Research: 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome
16 Mar, 2018 | 02:29h | UTC#ACC18 – 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
Commentaries: SMART-DATE: Myocardial Infarction Risk Higher with Six-Month Versus Twelve-Month DAPT – American College of Cardiology (free) AND Too Soon for 6-Month DAPT, Say SMART-DATE Investigators, Despite Positive Trial – TCTMD (free)
Related Guidelines: 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy (free) AND 2017 European Society of Cardiology focused update on dual antiplatelet therapy in coronary artery disease (free) AND 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease (free)